Pfizer, Inc. (PFE) Given a $37.00 Price Target at Jefferies Group LLC
Jefferies Group LLC set a $37.00 target price on Pfizer, Inc. (NYSE:PFE) in a research report sent to investors on Monday morning. The firm currently has a neutral rating on the biopharmaceutical company’s stock.
Several other equities research analysts have also recently weighed in on PFE. Berenberg Bank reissued a hold rating and issued a $36.00 price target (down previously from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. BMO Capital Markets reissued a buy rating and issued a $37.00 price target on shares of Pfizer in a research note on Thursday, September 14th. BidaskClub raised Pfizer from a strong sell rating to a sell rating in a research note on Saturday, August 5th. Cowen and Company set a $43.00 price target on Pfizer and gave the company a buy rating in a research note on Monday, August 14th. Finally, UBS AG reissued a buy rating and issued a $38.00 price target on shares of Pfizer in a research note on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $38.04.
Pfizer (PFE) opened at 35.97 on Monday. The company has a market cap of $213.93 billion, a PE ratio of 26.31 and a beta of 1.00. The firm’s 50-day moving average price is $33.78 and its 200-day moving average price is $33.53. Pfizer has a one year low of $29.83 and a one year high of $36.19.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the firm earned $0.64 EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer will post $2.56 earnings per share for the current fiscal year.
In other news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares in the company, valued at $5,097,715. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ian C. Read sold 197,168 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $6,703,712.00. Following the completion of the transaction, the chief executive officer now owns 580,318 shares in the company, valued at approximately $19,730,812. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock worth $15,813,961 in the last 90 days. Corporate insiders own 0.06% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Bogart Wealth LLC increased its position in shares of Pfizer by 20.4% during the second quarter. Bogart Wealth LLC now owns 15,451 shares of the biopharmaceutical company’s stock valued at $519,000 after acquiring an additional 2,615 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new stake in shares of Pfizer during the second quarter valued at approximately $403,000. Davidson Kempner Capital Management LP purchased a new stake in shares of Pfizer during the second quarter valued at approximately $5,039,000. W. E. Donoghue & Co. LLC purchased a new stake in shares of Pfizer during the second quarter valued at approximately $16,402,000. Finally, Intl Fcstone Inc. increased its position in shares of Pfizer by 444.3% during the second quarter. Intl Fcstone Inc. now owns 56,081 shares of the biopharmaceutical company’s stock valued at $1,884,000 after acquiring an additional 45,777 shares during the last quarter. 69.00% of the stock is owned by institutional investors.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.